GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan, said, “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR. He went on to say, “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.”

W. L. Gore & Associates, Inc. (Gore) announced the first implants in Japan of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). Gore reported that they have received Shonin approval from the Japanese Ministry of Health, Labour and Welfare to market the IBE and is currently in discussion regarding reimbursement for this region. The IBE is the first off-the-shelf iliac branch solution approved in Japan and the only device indicated for the endovascular treatment of common iliac artery aneursyms or aortoiliac aneursyms.

With more than 2,500 commercial implants worldwide, the device is a complete, fully engineered system (Gore designed iliac branch and internal iliac components), which received CE Mark in 2013, registration in Australia and New Zealand in 2015, and FDA and Health Canada approval in 2016.

Used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis, the IBE preserves blood flow in the external and internal iliac arteries. The IBE leverages the design and experience acquired from more than 20 years and 285,000 patients treated* with the GORE EXCLUDER AAA Endoprosthesis and utilizes the same durable, expanded polytetrafluoroethylene (ePTFE) graft and nitinol stent material. The IBE offers an All-in-One System with improved outcomes for the treatment of iliac artery aneurysms while preserving flow to the iliac arteries. Preservation of blood flow in the internal iliac arteries is found to avoid pelvic flow disruption and reduce the rate of complications that can include buttock claudication, sexual dysfunction, and colonic ischemia.

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan, said, “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR.  He went on to say, “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.”

The IBE system provides a treatment range of 6.5-13.5 mm for the internal iliac arteries, and a treatment range of 6.5-25 mm for the external iliac arteries. The delivery profile of the loaded catheter allows the use of a 16 Fr introducer sheath for the iliac branch component, and a flexible 12 Fr, reinforced introducer sheath for the internal iliac component.

Eric Zacharias, Vascular Business Leader added, “We are pleased to receive approval of this device in regions worldwide as it continues to provide an iliac branch solution for a patient group with a previously unmet treatment need.  Together with physicians, we have spent the past 20 years determining patient needs and continually working to improve our aortic family of devices to provide solutions physicians trust and patients count on.”  Zacharias concluded, “The IBE is an exciting innovation that stems from our mission to effectively treat aortic aneurysms through minimally invasive means.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles